FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Advisors Back Fampridine Efficacy, Safety

[ Price : $8.95]

Members of CDERs Peripheral and Central Nervous System Drug Advisory Committee say that Acordas fampridine is effective and safe f...

New Issues Seen in NME Safety Pilot Program

[ Price : $8.95]

FDA says that a pilot program for evaluating NMEs was labor intensive but produced results in terms of identifying new safety conc...

Comments Sought on New Animal Drug Experience Reports

[ Price : $8.95]

Federal Register Notice: FDA seeks comments on the requirements for recordkeeping and reports on experience with approved new anim...

Comments Sought on Device User Fee Form

[ Price : $8.95]

Federal Register Notice: FDA seeks comments on the Medical Device User Fee Cover Sheet.

Public Workshop on Diagnosing Respiratory Infections

[ Price : $8.95]

Federal Register Notice: FDA will co-sponsor a public workshop 11/13-13 on developing tests for diagnosing respiratory infections.

Future Success Lies in Innovation, Not Marketing: Wharton

[ Price : $8.95]

Wharton School faculty members say that the future of the pharmaceutical industry lies in innovative business models and new drugs...

Device Companies Taught to Use DTC Ads

[ Price : $8.95]

Panelists tell AdvaMed members to use DTC marketing to enhance public health and consumer understanding of new technologies and tr...

Committee Reports Out Pay-for-delay Ban

[ Price : $8.95]

The Senate Judiciary Committee approves legislation to ban most pay-for-delay agreements between innovator and generic drug compan...

Wound Dressing Special Controls Guidance

[ Price : $8.95]

FDA issues a guidance to support reclassifying wound dressing with Poly(diallyl dimethyl ammonium chloride) additive into Class 2 ...